Kancera

Mindre end 1K følgere

Oversigt

Investorkonsensus

Alle

Selskabspræsentationer

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse31.3.2026, 06.00

Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors

Pressemeddelelse2.3.2026, 06.00

Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Pressemeddelelse25.2.2026, 15.45

The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse12.2.2026, 16.45

Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines

Pressemeddelelse6.2.2026, 07.00

Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover

Selskabsmeddelelse22.12.2025, 07.00

Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover

Selskabsmeddelelse21.11.2025, 07.00

Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

Pressemeddelelse9.10.2025, 07.00

Novakand Pharma provides an update on the ongoing reverse take over process

Selskabsmeddelelse23.9.2025, 13.00

Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

Selskabsmeddelelse22.9.2025, 14.00

Kancera AB changes name to Novakand Pharma AB

Selskabsmeddelelse18.9.2025, 16.00

Kancera initiates process to seek stakeholders for a reverse take over

Selskabsmeddelelse28.8.2025, 06.00

Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

Selskabsmeddelelse12.8.2025, 06.00

Kancera terminates letter of intent with Recardio

Pressemeddelelse16.6.2025, 06.30

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Selskabsmeddelelse13.6.2025, 06.00

Kancera reports positive top-line results from the KANDOVA study

Selskabsmeddelelse5.6.2025, 06.00

Kancera reports positive outcome of pre-IND meeting with FDA

Pressemeddelelse27.5.2025, 06.39

Redeye: Kancera Q1 - Continued efforts with Recardio

Selskabsmeddelelse23.5.2025, 06.00

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Pressemeddelelse20.5.2025, 06.30

Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

Pressemeddelelse8.4.2025, 06.00

Kancera reports Last Patient Last Visit in the KANDOVA study

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.